Review





Similar Products

99
ATCC ct26 cells
PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of <t>CT26</t> tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Ct26 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ct26 cells/product/ATCC
Average 99 stars, based on 1 article reviews
ct26 cells - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

95
Addgene inc ppycag rnaseh1 wt plasmid
PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of <t>CT26</t> tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Ppycag Rnaseh1 Wt Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ppycag rnaseh1 wt plasmid/product/Addgene inc
Average 95 stars, based on 1 article reviews
ppycag rnaseh1 wt plasmid - by Bioz Stars, 2026-06
95/100 stars
  Buy from Supplier

93
Addgene inc pbabe puro gfp lamin a plasmid
PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of <t>CT26</t> tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Pbabe Puro Gfp Lamin A Plasmid, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbabe puro gfp lamin a plasmid/product/Addgene inc
Average 93 stars, based on 1 article reviews
pbabe puro gfp lamin a plasmid - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

86
Jackson Laboratory wt c57bl 6 mice
PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of <t>CT26</t> tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Wt C57bl 6 Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wt c57bl 6 mice/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
wt c57bl 6 mice - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Schuelke wt reovirus sargramostim gm csf
PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of <t>CT26</t> tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Wt Reovirus Sargramostim Gm Csf, supplied by Schuelke, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wt reovirus sargramostim gm csf/product/Schuelke
Average 86 stars, based on 1 article reviews
wt reovirus sargramostim gm csf - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Jackson Laboratory sex matched c57bl 6 wt mice
PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of <t>CT26</t> tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Sex Matched C57bl 6 Wt Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sex matched c57bl 6 wt mice/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
sex matched c57bl 6 wt mice - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Charles River Laboratories wt mice
PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of <t>CT26</t> tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Wt Mice, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wt mice/product/Charles River Laboratories
Average 86 stars, based on 1 article reviews
wt mice - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Shanghai Model Organisms Center wild type wt mice
PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of <t>CT26</t> tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.
Wild Type Wt Mice, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wild type wt mice/product/Shanghai Model Organisms Center
Average 86 stars, based on 1 article reviews
wild type wt mice - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Jackson Laboratory wt cd45 2 c57bl 6j
( A ) Representative gating strategy for sorting low, mid, and high IRES/Cap SLAM-LKS. ( B and C ) Colony formation (B) and size (C, mm 2 ) of Translator SLAM-LKS sorted on the basis of IRES/Cap ( n = 6). ( D and E ) Colony formation (D) and size (E, mm 2 ) of Translator GMP sorted on the basis of IRES/Cap ( n = 9). ( F ) Total protein synthesis rates of Translator GMP based on IRES/Cap measured by AF647-OPP MFI ( n = 3). ( G ) Colony formation of EMCV-IRES reporter-transduced CD34+CD90+EPCR+CD45RA− human cord blood sorted on the basis of IRES/Cap ( n = 3). ( H and I ) Colony formation of SLAM-LKS (H) and GMPs (I) based on RUNX1-IRES/Cap sorted from transplant recipients ( n = 3 and 2, respectively). ( J ) Primary competitive transplant schema. <t>Twenty</t> <t>CD45.2</t> SLAM-LKS sorted on the basis of IRES/Cap versus 200,000 CD45.1 whole BM cells in lethally irradiated CD45.1 recipients. Peripheral blood chimerism analyzed every four weeks through week 16. Created in BioRender. Li, D. (2026) https://BioRender.com/d7k2abt . ( K ) Total chimerism Translator SLAM-LKS based on IRES/Cap in primary recipients evaluated through week 16 ( n = 12). ( L ) Secondary competitive transplant schema. One million total BM cells were collected from primary recipients (16 weeks posttransplantation) and transplanted to lethally irradiated CD45.1 recipients. Created in BioRender. Li, D. (2026) https://BioRender.com/d7k2abt . ( M ) Total chimerism Translator SLAM-LKS based on IRES/Cap in secondary recipients through week 16 ( n = 12). ( N and O ) Representative image of the culture of a single low (N) or high (O) IRES/Cap SLAM-LKS after 5 days of culture. ( P and Q ) Pie charts depicting the percentage of wells with megakaryocytes (MK) after 5 days of culturing a single low (P) or high (Q) IRES/Cap Translator SLAM-LKS ( n = 20). Data show individual replicates and means ± SEM. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001. Significance was assessed using a two-way ANOVA with Dunnett’s one-way ANOVA (B to I) or an ANOVA with Tukey’s multiple comparisons test (K and M).
Wt Cd45 2 C57bl 6j, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/wt cd45 2 c57bl 6j/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
wt cd45 2 c57bl 6j - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

86
Jackson Laboratory male wt c57bl 6 mice
( A ) Representative gating strategy for sorting low, mid, and high IRES/Cap SLAM-LKS. ( B and C ) Colony formation (B) and size (C, mm 2 ) of Translator SLAM-LKS sorted on the basis of IRES/Cap ( n = 6). ( D and E ) Colony formation (D) and size (E, mm 2 ) of Translator GMP sorted on the basis of IRES/Cap ( n = 9). ( F ) Total protein synthesis rates of Translator GMP based on IRES/Cap measured by AF647-OPP MFI ( n = 3). ( G ) Colony formation of EMCV-IRES reporter-transduced CD34+CD90+EPCR+CD45RA− human cord blood sorted on the basis of IRES/Cap ( n = 3). ( H and I ) Colony formation of SLAM-LKS (H) and GMPs (I) based on RUNX1-IRES/Cap sorted from transplant recipients ( n = 3 and 2, respectively). ( J ) Primary competitive transplant schema. <t>Twenty</t> <t>CD45.2</t> SLAM-LKS sorted on the basis of IRES/Cap versus 200,000 CD45.1 whole BM cells in lethally irradiated CD45.1 recipients. Peripheral blood chimerism analyzed every four weeks through week 16. Created in BioRender. Li, D. (2026) https://BioRender.com/d7k2abt . ( K ) Total chimerism Translator SLAM-LKS based on IRES/Cap in primary recipients evaluated through week 16 ( n = 12). ( L ) Secondary competitive transplant schema. One million total BM cells were collected from primary recipients (16 weeks posttransplantation) and transplanted to lethally irradiated CD45.1 recipients. Created in BioRender. Li, D. (2026) https://BioRender.com/d7k2abt . ( M ) Total chimerism Translator SLAM-LKS based on IRES/Cap in secondary recipients through week 16 ( n = 12). ( N and O ) Representative image of the culture of a single low (N) or high (O) IRES/Cap SLAM-LKS after 5 days of culture. ( P and Q ) Pie charts depicting the percentage of wells with megakaryocytes (MK) after 5 days of culturing a single low (P) or high (Q) IRES/Cap Translator SLAM-LKS ( n = 20). Data show individual replicates and means ± SEM. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001. Significance was assessed using a two-way ANOVA with Dunnett’s one-way ANOVA (B to I) or an ANOVA with Tukey’s multiple comparisons test (K and M).
Male Wt C57bl 6 Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/male wt c57bl 6 mice/product/Jackson Laboratory
Average 86 stars, based on 1 article reviews
male wt c57bl 6 mice - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of CT26 tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Journal: Bioactive Materials

Article Title: Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer

doi: 10.1016/j.bioactmat.2026.03.012

Figure Lengend Snippet: PGE2 blockade modulates immune cell phenotypes in antitumor resp onses. (A) Inflammatory gene expression across cancer types (GEPIA2 database). (B) Gene expression of Il1b , Cxcl8 , and Lif in colon adenocarcinoma (COAD) tumor tissue and normal tissue (GEPIA2 database). (C and D) Correlation between Ptgs2 and inflammatory genes in various cancers (C) and COAD (D) (TIMER 2.0). (E) Schematic of immune cells co-incubated with CXB treated tumor conditional medium (TCM) (Source material from BioRender). (F and G) Cell viability (F) and Cell cycle arrest (G) detection of CT26 tumor cells treated with gradient concentrations of CXB; n = 3. (H) PGE2 concentration in CT26 cell supernatants; n = 3. (I) The proportion of CD103 + DC within BMDCs after CXB treatments in vitro ; n = 3. (J and K) Maturation (J) and Antigen processing capability (K) on BMDCs; n = 3. (L – N) Flow charts of CD86 or CD206 expression on Raw 264.7 cells (L). Quantification of CD86 (M) and CD206 (N) expression on Raw 264.7 cells; n = 3. (O and P) Flow charts (O) and Quantification (P) of CD69 and CD137 expression on splenic T cells exposed to CXB-pretreated TCM; n = 3. (Q) IFN-γ secretion by T cells co-cultured with CXB-pretreated TCM; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Article Snippet: CT26 cells and Raw 264.7 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Gene Expression, Incubation, Concentration Assay, In Vitro, Expressing, Cell Culture

Sustained PGE2 blockade prompts immune activ ation. (A) Structure of hydrogel matrix and scheme of Gel-CXB preparation (Source material from BioRender). (B) Microstructure of the hydrogel. (C) Rheological evaluation of Gel-CXB. (D) CXB release from Gel-CXB in PBS or PBS containing 0.5 mM H 2 O 2 ; n = 3. (E and F) Flow chart (E) and Quantification (F) of CD103 + DC within BMDCs; n = 3. (G and H) Flow chart (G) and Heatmap (H) of costimulatory molecular expression on CD103 - DC, CD103 + DC, or total DC with different treatments; n = 3. (I and J) CXCL9 (I) and Costimulatory molecular expression (J) on cDC1; n = 3. (K – M) CD86 and CD206 expression (K), MHC-II expression (L), and Antigen processing capability (M) of BMDMs incubated with different TCM; n = 3. (N and O) CD69 (N) and CD137 (O) expression on CD8 + T cells co-incubated with different TCM; n = 3. (P) Scheme of Gel-CXB-regulated CT26 TME at different time points in vivo . (Q) Changes of several immune cells within TME at Day 1, 5, and 9; n = 3. (R) Tumor volume of mice treated with CXB alone or Gel-CXB in vivo ; n = 5. (S) CD137 expression on CD8 + T cells in vivo ; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Journal: Bioactive Materials

Article Title: Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer

doi: 10.1016/j.bioactmat.2026.03.012

Figure Lengend Snippet: Sustained PGE2 blockade prompts immune activ ation. (A) Structure of hydrogel matrix and scheme of Gel-CXB preparation (Source material from BioRender). (B) Microstructure of the hydrogel. (C) Rheological evaluation of Gel-CXB. (D) CXB release from Gel-CXB in PBS or PBS containing 0.5 mM H 2 O 2 ; n = 3. (E and F) Flow chart (E) and Quantification (F) of CD103 + DC within BMDCs; n = 3. (G and H) Flow chart (G) and Heatmap (H) of costimulatory molecular expression on CD103 - DC, CD103 + DC, or total DC with different treatments; n = 3. (I and J) CXCL9 (I) and Costimulatory molecular expression (J) on cDC1; n = 3. (K – M) CD86 and CD206 expression (K), MHC-II expression (L), and Antigen processing capability (M) of BMDMs incubated with different TCM; n = 3. (N and O) CD69 (N) and CD137 (O) expression on CD8 + T cells co-incubated with different TCM; n = 3. (P) Scheme of Gel-CXB-regulated CT26 TME at different time points in vivo . (Q) Changes of several immune cells within TME at Day 1, 5, and 9; n = 3. (R) Tumor volume of mice treated with CXB alone or Gel-CXB in vivo ; n = 5. (S) CD137 expression on CD8 + T cells in vivo ; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Article Snippet: CT26 cells and Raw 264.7 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Expressing, Incubation, In Vivo

TRANS inhibits tumor growth and enhances local and systemic immune resp onses. (A) Scheme of GC, GCF, or TRANS preparation (Source material from BioRender). (B) Microstructure of GC and TRANS. (C) Experimental design for administration and immune cell analysis. (D) Tumor growth curves under different treatments; n = 5. (E) Tumor weight post-treatment; n = 5. (F – H) CD45 + leukocytes and CD11c + DCs (F), CD86 + M1 and CD206 + M2 macrophages (G), and Tumor-infiltrating CD8 + T cells (H) within TME; n = 5. (I – L) Mature DCs (I), CD8α + cDC1s (J), CD4 + and CD8 + T cells (K) and CD69 + CD8 + T cells (L) in lymph nodes; n = 5. (M – Q) CD11c + MHC II + DCs (M), CD8α + cDC1s (N), CD4 + and CD8 + T cells (O), CD69 + CD8 + T cells (P), and IFN-γ + CD8 + T cells (Q) in the spleen; n = 5. (R – T) CD8 + T cells (R), The ratio of CD8 + T /CD4 + T cells (S), and IFN-γ levels (T) in blood; n = 5. (U) IFN-γ + CD4 + T and IFN-γ + CD8 + T cells with ex vivo stimulation of PMA/ionomycin for 6 h; n = 3. (V) Apoptosis of CT26 cells co-incubated with splenic T cells for 24 h; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Journal: Bioactive Materials

Article Title: Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer

doi: 10.1016/j.bioactmat.2026.03.012

Figure Lengend Snippet: TRANS inhibits tumor growth and enhances local and systemic immune resp onses. (A) Scheme of GC, GCF, or TRANS preparation (Source material from BioRender). (B) Microstructure of GC and TRANS. (C) Experimental design for administration and immune cell analysis. (D) Tumor growth curves under different treatments; n = 5. (E) Tumor weight post-treatment; n = 5. (F – H) CD45 + leukocytes and CD11c + DCs (F), CD86 + M1 and CD206 + M2 macrophages (G), and Tumor-infiltrating CD8 + T cells (H) within TME; n = 5. (I – L) Mature DCs (I), CD8α + cDC1s (J), CD4 + and CD8 + T cells (K) and CD69 + CD8 + T cells (L) in lymph nodes; n = 5. (M – Q) CD11c + MHC II + DCs (M), CD8α + cDC1s (N), CD4 + and CD8 + T cells (O), CD69 + CD8 + T cells (P), and IFN-γ + CD8 + T cells (Q) in the spleen; n = 5. (R – T) CD8 + T cells (R), The ratio of CD8 + T /CD4 + T cells (S), and IFN-γ levels (T) in blood; n = 5. (U) IFN-γ + CD4 + T and IFN-γ + CD8 + T cells with ex vivo stimulation of PMA/ionomycin for 6 h; n = 3. (V) Apoptosis of CT26 cells co-incubated with splenic T cells for 24 h; n = 3. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Article Snippet: CT26 cells and Raw 264.7 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: Cell Analysis, Ex Vivo, Incubation

TRANS inhibits tumor metastasis and induces immune memory in vivo . (A) Experimental design for secondary tumor model. (B and C) Tumor volume curves of primary tumor (B) and secondary tumor (C) during different therapy; n = 5. (D and E) Statistical diagram (D) and flow charts (E) of T cells within secondary tumors; n = 5. (F) Immunofluorescence images of immune cell in primary tumor. (G) Schematic of lung metastasis tumor model and treatment regimen. Mice received subcutaneous and intravenous injections of CT26-Luc. (H – J) In vivo images (H), Primary tumor volume curves (I), and Average radiance in lungs (J) of CT26-Luc tumor-bearing mice; n = 5. (K – M) Lung image (K), Lung metastasis foci counts and weights (L), and H&E staining of lungs (M) from CT26-Luc tumor-bearing mice; n = 5. (N) Schematic of liver metastasis tumor model and treatment regimen. Mice received subcutaneous CT26 tumor and splenic CT26-Luc injections. (O and P) In vivo imaging (O) and Individual radiance in livers (P) of CT26-Luc tumor-bearing mice; n = 10. (Q – S) Live images (Q), Liver weights (R), and H&E staining images of livers (S) from PBS- or TRANS-treated mice; n = 5. (T) Scheme of tumor rechallenge model. (U) Tumor changes in mice rechallenged with CT26 or 4T1; n = 9. (V) Central memory (T CM ) and effector memory (T EM ) gated on CD8 + T cells; n = 5. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Journal: Bioactive Materials

Article Title: Chronic inflammation-responsive hydrogel restores myeloid-T cell crosstalk to reinvigorate antitumor immunity against metastatic colorectal cancer

doi: 10.1016/j.bioactmat.2026.03.012

Figure Lengend Snippet: TRANS inhibits tumor metastasis and induces immune memory in vivo . (A) Experimental design for secondary tumor model. (B and C) Tumor volume curves of primary tumor (B) and secondary tumor (C) during different therapy; n = 5. (D and E) Statistical diagram (D) and flow charts (E) of T cells within secondary tumors; n = 5. (F) Immunofluorescence images of immune cell in primary tumor. (G) Schematic of lung metastasis tumor model and treatment regimen. Mice received subcutaneous and intravenous injections of CT26-Luc. (H – J) In vivo images (H), Primary tumor volume curves (I), and Average radiance in lungs (J) of CT26-Luc tumor-bearing mice; n = 5. (K – M) Lung image (K), Lung metastasis foci counts and weights (L), and H&E staining of lungs (M) from CT26-Luc tumor-bearing mice; n = 5. (N) Schematic of liver metastasis tumor model and treatment regimen. Mice received subcutaneous CT26 tumor and splenic CT26-Luc injections. (O and P) In vivo imaging (O) and Individual radiance in livers (P) of CT26-Luc tumor-bearing mice; n = 10. (Q – S) Live images (Q), Liver weights (R), and H&E staining images of livers (S) from PBS- or TRANS-treated mice; n = 5. (T) Scheme of tumor rechallenge model. (U) Tumor changes in mice rechallenged with CT26 or 4T1; n = 9. (V) Central memory (T CM ) and effector memory (T EM ) gated on CD8 + T cells; n = 5. Data are presented as mean ± SD, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. Significance was calculated using One-way ANOVA.

Article Snippet: CT26 cells and Raw 264.7 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA).

Techniques: In Vivo, Immunofluorescence, Staining, In Vivo Imaging

( A ) Representative gating strategy for sorting low, mid, and high IRES/Cap SLAM-LKS. ( B and C ) Colony formation (B) and size (C, mm 2 ) of Translator SLAM-LKS sorted on the basis of IRES/Cap ( n = 6). ( D and E ) Colony formation (D) and size (E, mm 2 ) of Translator GMP sorted on the basis of IRES/Cap ( n = 9). ( F ) Total protein synthesis rates of Translator GMP based on IRES/Cap measured by AF647-OPP MFI ( n = 3). ( G ) Colony formation of EMCV-IRES reporter-transduced CD34+CD90+EPCR+CD45RA− human cord blood sorted on the basis of IRES/Cap ( n = 3). ( H and I ) Colony formation of SLAM-LKS (H) and GMPs (I) based on RUNX1-IRES/Cap sorted from transplant recipients ( n = 3 and 2, respectively). ( J ) Primary competitive transplant schema. Twenty CD45.2 SLAM-LKS sorted on the basis of IRES/Cap versus 200,000 CD45.1 whole BM cells in lethally irradiated CD45.1 recipients. Peripheral blood chimerism analyzed every four weeks through week 16. Created in BioRender. Li, D. (2026) https://BioRender.com/d7k2abt . ( K ) Total chimerism Translator SLAM-LKS based on IRES/Cap in primary recipients evaluated through week 16 ( n = 12). ( L ) Secondary competitive transplant schema. One million total BM cells were collected from primary recipients (16 weeks posttransplantation) and transplanted to lethally irradiated CD45.1 recipients. Created in BioRender. Li, D. (2026) https://BioRender.com/d7k2abt . ( M ) Total chimerism Translator SLAM-LKS based on IRES/Cap in secondary recipients through week 16 ( n = 12). ( N and O ) Representative image of the culture of a single low (N) or high (O) IRES/Cap SLAM-LKS after 5 days of culture. ( P and Q ) Pie charts depicting the percentage of wells with megakaryocytes (MK) after 5 days of culturing a single low (P) or high (Q) IRES/Cap Translator SLAM-LKS ( n = 20). Data show individual replicates and means ± SEM. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001. Significance was assessed using a two-way ANOVA with Dunnett’s one-way ANOVA (B to I) or an ANOVA with Tukey’s multiple comparisons test (K and M).

Journal: Science Advances

Article Title: Shifting IRES versus Cap-initiated translation during homeostatic stem cell differentiation and stress

doi: 10.1126/sciadv.adz7896

Figure Lengend Snippet: ( A ) Representative gating strategy for sorting low, mid, and high IRES/Cap SLAM-LKS. ( B and C ) Colony formation (B) and size (C, mm 2 ) of Translator SLAM-LKS sorted on the basis of IRES/Cap ( n = 6). ( D and E ) Colony formation (D) and size (E, mm 2 ) of Translator GMP sorted on the basis of IRES/Cap ( n = 9). ( F ) Total protein synthesis rates of Translator GMP based on IRES/Cap measured by AF647-OPP MFI ( n = 3). ( G ) Colony formation of EMCV-IRES reporter-transduced CD34+CD90+EPCR+CD45RA− human cord blood sorted on the basis of IRES/Cap ( n = 3). ( H and I ) Colony formation of SLAM-LKS (H) and GMPs (I) based on RUNX1-IRES/Cap sorted from transplant recipients ( n = 3 and 2, respectively). ( J ) Primary competitive transplant schema. Twenty CD45.2 SLAM-LKS sorted on the basis of IRES/Cap versus 200,000 CD45.1 whole BM cells in lethally irradiated CD45.1 recipients. Peripheral blood chimerism analyzed every four weeks through week 16. Created in BioRender. Li, D. (2026) https://BioRender.com/d7k2abt . ( K ) Total chimerism Translator SLAM-LKS based on IRES/Cap in primary recipients evaluated through week 16 ( n = 12). ( L ) Secondary competitive transplant schema. One million total BM cells were collected from primary recipients (16 weeks posttransplantation) and transplanted to lethally irradiated CD45.1 recipients. Created in BioRender. Li, D. (2026) https://BioRender.com/d7k2abt . ( M ) Total chimerism Translator SLAM-LKS based on IRES/Cap in secondary recipients through week 16 ( n = 12). ( N and O ) Representative image of the culture of a single low (N) or high (O) IRES/Cap SLAM-LKS after 5 days of culture. ( P and Q ) Pie charts depicting the percentage of wells with megakaryocytes (MK) after 5 days of culturing a single low (P) or high (Q) IRES/Cap Translator SLAM-LKS ( n = 20). Data show individual replicates and means ± SEM. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001. Significance was assessed using a two-way ANOVA with Dunnett’s one-way ANOVA (B to I) or an ANOVA with Tukey’s multiple comparisons test (K and M).

Article Snippet: WT CD45.2 C57BL/6J (strain #000664), CD45.1 (B6.SJL- Ptprc a Pepc b /BoyJ; strain #002014), KH2/iCas9 [B6;129S4- Gt(ROSA)26Sor tm1(rtTA*M2)Jae Col1a1 tm1(tetO-cas9)Sho /J; strain #029415], Rpl24 Bst (C57BLKS-Rpl24 Bst /J; strain #000516), and NSG mice (NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ; strain #005557) were purchased from the Jackson Laboratory.

Techniques: Irradiation